Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...

Antibody–drug conjugates (ADCs) represent a breakthrough in cancer therapy, combining the precision of monoclonal antibodies with powerful chemotherapeutic drugs. While ADC development is accelerating ...

We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...

Kadcyla and Perjeta, the new class of drugs launched in India in October, cost Rs 2,10,000 (200 ml) and Rs 2,49,000 for a dosage, respectively. ET verified the price with several chemists and ...